"Designing Growth Strategies is in our DNA"

Ophthalmic Disease Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Anti-inflammatory, Anti-infectives, Anti-VEGF, and Anti-glaucoma), By Dosage Form (Solid, Liquid, and Semisolid), By Disease Indication (Glaucoma, Dry Eye Disease, Retinal Diseases, and Allergy & Infections), By Distribution Channel (Hospital Pharmacies and Retail & Online Pharmacies), and Regional Forecast, 2023-2030

Region : Global | Format: PDF | Report ID: FBI100441

 

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Major Ophthalmic Diseases, in Key Countries/ Region, 2022
    2. Pipeline Analysis, Key Players
    3. Patent Snapshot, Key Players
    4. Recent Industry Developments Such as Partnerships, Mergers & Acquisitions
    5. Regulatory Scenario for Key Countries
    6. Reimbursement Scenario for Key Countries
    7. Impact of COVID-19 on the Market
  5. Global Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anti-inflammatory
      2. Anti-infectives
      3. Anti-VEGF
      4. Anti-glaucoma
        1. Beta Blockers
        2. Prostaglandins Analogs
        3. Alpha Adrenergic Agonists
        4. Carbonic Anhydrase Inhibitors
        5. Combination Drugs
        6. Others
      5. Others
    2. Market Analysis, Insights and Forecast – By Dosage Form
      1. Solid
      2. Liquid
      3. Semi-solid
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Glaucoma
        1. Open Angle Glaucoma
        2. Angle Closure Glaucoma
        3. Others
      2. Dry Eye Disease
      3. Retinal Diseases
        1. Diabetic Macular Edema (DME)
        2. Macular Degeneration (AMD)
        3. Diabetic Retinopathy (DR)
        4. Retinal Vein Occlusion (RVO)
        5. Others
      4. Allergy & Infections
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies & Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anti-inflammatory
      2. Anti-infectives
      3. Anti-VEGF
      4. Anti-glaucoma
        1. Beta Blockers
        2. Prostaglandins Analogs
        3. Alpha Adrenergic Agonists
        4. Carbonic Anhydrase Inhibitors
        5. Combination Drugs
        6. Others
      5. Others
    2. Market Analysis, Insights and Forecast – By Dosage Form
      1. Solid
      2. Liquid
      3. Semi-solid
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Glaucoma
        1. Open Angle Glaucoma
        2. Angle Closure Glaucoma
        3. Others
      2. Dry Eye Disease
      3. Retinal Diseases
        1. Diabetic Macular Edema (DME)
        2. Macular Degeneration (AMD)
        3. Diabetic Retinopathy (DR)
        4. Retinal Vein Occlusion (RVO)
        5. Others
      4. Allergy & Infections
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies & Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada
  7. Europe Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anti-inflammatory
      2. Anti-infectives
      3. Anti-VEGF
      4. Anti-glaucoma
        1. Beta Blockers
        2. Prostaglandins Analogs
        3. Alpha Adrenergic Agonists
        4. Carbonic Anhydrase Inhibitors
        5. Combination Drugs
        6. Others
      5. Others
    2. Market Analysis, Insights and Forecast – By Dosage Form
      1. Solid
      2. Liquid
      3. Semi-solid
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Glaucoma
        1. Open Angle Glaucoma
        2. Angle Closure Glaucoma
        3. Others
      2. Dry Eye Disease
      3. Retinal Diseases
        1. Diabetic Macular Edema (DME)
        2. Macular Degeneration (AMD)
        3. Diabetic Retinopathy (DR)
        4. Retinal Vein Occlusion (RVO)
        5. Others
      4. Allergy & Infections
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies & Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. U.K
      2. Germany
      3. France
      4. Spain
      5. Italy
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anti-inflammatory
      2. Anti-infectives
      3. Anti-VEGF
      4. Anti-glaucoma
        1. Beta Blockers
        2. Prostaglandins Analogs
        3. Alpha Adrenergic Agonists
        4. Carbonic Anhydrase Inhibitors
        5. Combination Drugs
        6. Others
      5. Others
    2. Market Analysis, Insights and Forecast – By Dosage Form
      1. Solid
      2. Liquid
      3. Semi-solid
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Glaucoma
        1. Open Angle Glaucoma
        2. Angle Closure Glaucoma
        3. Others
      2. Dry Eye Disease
      3. Retinal Diseases
        1. Diabetic Macular Edema (DME)
        2. Macular Degeneration (AMD)
        3. Diabetic Retinopathy (DR)
        4. Retinal Vein Occlusion (RVO)
        5. Others
      4. Allergy & Infections
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies & Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. Japan
      2. China
      3. India
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  9. Latin America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anti-inflammatory
      2. Anti-infectives
      3. Anti-VEGF
      4. Anti-glaucoma
        1. Beta Blockers
        2. Prostaglandins Analogs
        3. Alpha Adrenergic Agonists
        4. Carbonic Anhydrase Inhibitors
        5. Combination Drugs
        6. Others
      5. Others
    2. Market Analysis, Insights and Forecast – By Dosage Form
      1. Solid
      2. Liquid
      3. Semi-solid
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Glaucoma
        1. Open Angle Glaucoma
        2. Angle Closure Glaucoma
        3. Others
      2. Dry Eye Disease
      3. Retinal Diseases
        1. Diabetic Macular Edema (DME)
        2. Macular Degeneration (AMD)
        3. Diabetic Retinopathy (DR)
        4. Retinal Vein Occlusion (RVO)
        5. Others
      4. Allergy & Infections
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies & Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Anti-inflammatory
      2. Anti-infectives
      3. Anti-VEGF
      4. Anti-glaucoma
        1. Beta Blockers
        2. Prostaglandins Analogs
        3. Alpha Adrenergic Agonists
        4. Carbonic Anhydrase Inhibitors
        5. Combination Drugs
        6. Others
      5. Others
    2. Market Analysis, Insights and Forecast – By Dosage Form
      1. Solid
      2. Liquid
      3. Semi-solid
    3. Market Analysis, Insights and Forecast – By Disease Indication
      1. Glaucoma
        1. Open Angle Glaucoma
        2. Angle Closure Glaucoma
        3. Others
      2. Dry Eye Disease
      3. Retinal Diseases
        1. Diabetic Macular Edema (DME)
        2. Macular Degeneration (AMD)
        3. Diabetic Retinopathy (DR)
        4. Retinal Vein Occlusion (RVO)
        5. Others
      4. Allergy & Infections
      5. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies & Online Pharmacies
    5. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. GCC
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis
    1. Global Market Share Analysis (2022)
    2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
      1. Viatris Inc.
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      2. Novartis AG
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      3. AbbVie Inc.
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      4. F. Hoffmann-La Roche Ltd.
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      5. Regeneron Pharmaceuticals, Inc.
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      6. Santen Pharmaceutical Co., Ltd.
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      7. Bayer AG
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      8. Bausch & Lomb Incorporated
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
      9. Merck KGaA
        1. Overview,
        2. Product,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. financials (Based on Availability)
Read Less

Figure 1:  Global Ophthalmic Disease Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2022 & 2030

Figure 2:  Global Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2022 & 2030

Figure 3:  Global Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2022 & 2030

Figure 4:  Global Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2022 & 2030

Figure 5:  Global Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2022 & 2030

Figure 6:  Global Ophthalmic Disease Therapeutics Market Value (USD billion), by Region, 2022 & 2030

Figure 7:  North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2022 & 2030

Figure 8:  North America Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2022

Figure 9:  North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2022 & 2030

Figure 10:  North America Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2022

Figure 11:  North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2022 & 2030

Figure 12:  North America Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2022

Figure 13:  North America Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2022 & 2030

Figure 14:  North America Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2022

Figure 15:  North America Ophthalmic Disease Therapeutics Market Value (USD billion), By Country, 2022 & 2030

Figure 16:  North America Ophthalmic Disease Therapeutics Market Value Share (%), By Country, 2022

Figure 17:  Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2022 & 2030

Figure 18:  Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2022

Figure 19:  Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2022 & 2030

Figure 20:  Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2022

Figure 21:  Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2022 & 2030

Figure 22:  Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2022

Figure 23:  Europe Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2022 & 2030

Figure 24:  Europe Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2022

Figure 25:  Europe Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2022 & 2030

Figure 26:  Europe Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2022

Figure 27:  Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2022 & 2030

Figure 28:  Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2022

Figure 29:  Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2022 & 2030

Figure 30:  Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2022

Figure 31:  Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2022 & 2030

Figure 32:  Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2022

Figure 33:  Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2022 & 2030

Figure 34:  Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2022

Figure 35:  Asia Pacific Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2022 & 2030

Figure 36:  Asia Pacific Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2022

Figure 37:  Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2022 & 2030

Figure 38:  Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2022

Figure 39:  Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2022 & 2030

Figure 40:  Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2022

Figure 41:  Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2022 & 2030

Figure 42:  Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2022

Figure 43:  Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2022 & 2030

Figure 44:  Latin America Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2022

Figure 45:  Latin America Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2022 & 2030

Figure 46:  Latin America Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2022

Figure 47:  Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Drug Class, 2022 & 2030

Figure 48:  Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Drug Class, 2022

Figure 49:  Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Dosage Form, 2022 & 2030

Figure 50:  Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Dosage Form, 2022

Figure 51:  Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Disease Indication, 2022 & 2030

Figure 52:  Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Disease Indication, 2022

Figure 53:  Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), by Distribution Channel, 2022 & 2030

Figure 54:  Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), by Distribution Channel, 2022

Figure 55:  Middle East & Africa Ophthalmic Disease Therapeutics Market Value (USD billion), By Country/ Sub-region, 2022 & 2030

Figure 56:  Middle East & Africa Ophthalmic Disease Therapeutics Market Value Share (%), By Country/ Sub-region, 2022

Figure 57:  Global Ophthalmic Disease Therapeutics Market Share (%), By Company, 2022

Table 1:  Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2030

Table 2:  Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2019-2030

Table 3:  Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2019-2030

Table 4:  Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2030

Table 5:  Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2019-2030

Table 6:  Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2019-2030

Table 7:  Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2030

Table 8:  Global Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Region, 2019-2030

Table 9:  North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2030

Table 10:  North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2019-2030

Table 11:  North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2019-2030

Table 12:  North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2030

Table 13:  North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2019-2030

Table 14:  North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2019-2030

Table 15:  North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2030

Table 16:  North America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country, 2019-2030

Table 17:  Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2030

Table 18:  Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2019-2030

Table 19:  Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2019-2030

Table 20:  Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2030

Table 21:  Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2019-2030

Table 22:  Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2019-2030

Table 23:  Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2030

Table 24:  Europe Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2030

Table 25:  Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2030

Table 26:  Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2019-2030

Table 27:  Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2019-2030

Table 28:  Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2030

Table 29:  Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2019-2030

Table 30:  Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2019-2030

Table 31:  Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2030

Table 32:  Asia Pacific Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2030

Table 33:  Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2030

Table 34:  Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2019-2030

Table 35:  Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2019-2030

Table 36:  Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2019-2030

Table 37:  Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2019-2030

Table 38:  Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2030

Table 39:  Latin America Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2030

Table 40:  Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2030

Table 41:  Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Anti-glaucoma, 2019-2030

Table 42:  Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Dosage Form, 2019-2030

Table 43:  Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Glaucoma, 2019-2030

Table 44:  Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Retinal Diseases, 2019-2030

Table 45:  Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2030

Table 46:  Middle East & Africa Ophthalmic Disease Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2030

  • Feb, 2023
  • 2022
  • 2019-2021
  • 180

    CHOOSE LICENSE TYPE

  • $4850
    $5850
    $6850

Healthcare Clients

3M
abbvie
Amgen
Ansell
Fresenius
Galemed
Grifols
Ipsos
iqvia
Johnson
Jubilant
Lek
Pfizer
Roche
Siemens Healthineers
Styker
uniliver

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- UGlobal hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X